



# AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: <http://www.ajptr.com/>

## Marketing development of Affordable Medicines

**Chaya M\*, Bhoomika R, Shivani S, Varshitha OS**

*Department of Pharmaceutical marketing management, Sree Siddaganga College of Pharmacy, 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 feet Road, Batwadi, Tumkur572103. Karnataka (India)*

### ABSTRACT

Access to affordable medicines remains a critical challenge in global healthcare, particularly in low and middle-income countries, where high drug costs, patent restrictions, and fragmented distribution systems often prevent patients from receiving essential treatments<sup>1</sup>. While the availability of generics and biosimilars has expanded opportunities for cost reduction, uptake is frequently hindered by regulatory barriers, supply chain inefficiencies, and skepticism among healthcare providers and patients. This article explores the role of marketing strategies in improving access to affordable medicines<sup>2</sup>. It examines pricing approaches such as tiered pricing, advance market commitments, and patient-assistance programs, alongside distribution mechanisms including pooled procurement, local manufacturing, and public-private partnerships. Product strategies, including voluntary licensing, generics, and biosimilars, are discussed, highlighting their impact on both cost and accessibility. The importance of promotional and awareness campaigns in building trust and encouraging the use of affordable alternatives is also emphasized. To illustrate these strategies, global case studies are presented, including Thailand's compulsory licensing for HIV drugs<sup>3</sup>, India's Jan Aushadhi scheme, Gavi's Advance Market Commitment for pneumococcal vaccines, and the Clinton Health Access Initiative's HIV self-testing program. The article also discusses challenges such as regulatory and legal hurdles, financial sustainability, stakeholder coordination, and public perception. Finally, future directions are proposed, focusing on technological integration, policy advocacy, and collaborative frameworks to strengthen equitable access.

**Keywords:** Affordable medicines, Biosimilars, Generics, Global health access, Marketing strategies, Public-private partnerships, Tiered pricing.

\*Corresponding Author Email: [bhoomibhavana03@gmail.com](mailto:bhoomibhavana03@gmail.com)

Received 10 September 2025, Accepted 10 October 2025

Please cite this article as: Chaya M *et al.*, Marketing development of Affordable Medicines. American Journal of PharmTech Research 2025.

## INTRODUCTION

Affordable medicine refers to drugs and treatments that are reasonably priced and accessible without causing financial hardship. It ensures that patients, including low- and middle-income groups, can obtain essential medicines when needed. The concept emphasizes equity, so vulnerable populations are not excluded from care. Affordability must align with quality and safety, without compromising effectiveness. It is a vital element of universal health coverage and global public health. Ensuring that medicines remain affordable and accessible is one of the biggest challenges in global healthcare today<sup>1</sup>. While scientific progress has led to remarkable breakthroughs in treatment, the rising costs of many essential drugs have created deep inequalities. Millions of people, especially in low- and middle-income countries, are unable to access the therapies they need. The World Health Organization has repeatedly underlined that affordable medicine is not just an economic issue but a vital component of universal health coverage. Yet barriers such as strict patent protections, fragmented supply chains, and persistent doubts about generic drugs continue to limit progress.

Against this backdrop, the marketing development of affordable medicines has gained importance as both a public health necessity and a commercial strategy<sup>2</sup>. Unlike traditional marketing, which often focuses on profit maximization, this approach blends social responsibility with innovative business models. Governments, pharmaceutical companies, and non-profit organizations are experimenting with solutions such as pooled procurement, tiered pricing, voluntary licensing, and awareness campaigns. At the same time, efforts to educate patients and healthcare providers about the reliability of generics and biosimilars are helping to build trust. This article explores these approaches in detail, drawing on global experiences and case studies to show how marketing strategies can play a central role in making medicines more affordable and accessible.

## LITERATURE REVIEW:

The literature highlights several key strategies employed to enhance the accessibility of affordable medicines<sup>3</sup>:

### **Tiered Pricing:**

Adjusting prices based on the economic status of different countries to make medicines more affordable in low-income regions.

### **Voluntary Licensing:**

Allowing generic manufacturers to produce patented medicines, thereby increasing competition and reducing prices.

### **Public–Private Partnerships:**

Collaborations between governments and private entities to pool resources and negotiate better prices.

### Awareness Campaigns:


Educating both healthcare providers and patients about the efficacy and safety of generic medicines to build trust and encourage their use.

Despite these efforts, challenges such as regulatory hurdles, market dynamics, and public perception continue to impede the widespread adoption of affordable medicines<sup>4</sup>.

### Marketing Development strategies:

Developing strategies to market affordable medicines effectively requires a careful balance between public health goals and commercial considerations. Unlike traditional pharmaceutical marketing, which often emphasizes profit, the marketing of affordable medicines focuses on making essential treatments accessible, reliable, and trusted.

### Pricing Approaches:



**Figure 1: Distribution of marketing strategies**

Price is one of the most significant barriers to access. Many programs now use tiered or differential pricing, offering lower prices in low- and middle-income countries compared to wealthier markets. Programs such as Pfizer's "Accord for a Healthier World" and Novartis Access provide essential medicines at minimal or not-for-profit costs. Advance Market Commitments (AMCs), particularly for vaccines, guarantee a market if manufacturers supply at lower prices, encouraging production while keeping costs down. Additionally, patient-assistance programs and direct donations help those who would otherwise be unable to afford treatment<sup>5</sup>.

**Distribution Mechanisms:**

Even when medicines are affordable, they must reach the people who need them. Pooled procurement—used by organizations such as Gavi, UNICEF, and the Global Fund—allows multiple countries to negotiate better prices and maintain consistent supply. Local manufacturing, like India’s Jan Aushadhi scheme, reduces import costs and helps distribute low-cost generics more widely. Public–private partnerships (PPPs) enhance logistics and supply chain efficiency, combining government infrastructure with private-sector expertise to ensure medicines reach urban and remote areas<sup>6</sup>.

**Product Strategies:**

Generics and biosimilars are central to affordability. Once patents expire, competition can significantly reduce prices. Voluntary licensing agreements, facilitated by entities such as the Medicines Patent Pool, enable generic production in low-income countries. Where voluntary options are insufficient, governments may issue compulsory licenses, as seen in Thailand and Brazil, to expand access. Patent pooling also allows multiple manufacturers to enter the market, increasing competition and maintaining quality standards<sup>7</sup>.

**Promotional and Awareness Efforts:**

Even when affordable medicines are available, perceptions of quality can hinder uptake. Educational campaigns targeting healthcare providers and patients are critical to building confidence in generics and biosimilars. NGOs, international agencies, and government initiatives often run social marketing programs that highlight success stories and the safety of low-cost alternatives. Provider training encourages rational prescribing and reinforces trust in affordable medicines<sup>8</sup>.

**Integrated Approach:**

For maximum effectiveness, pricing, distribution, product strategies, and awareness campaigns must work together. Integrated approaches ensure that medicines are not only affordable but also accessible and trusted. Collaboration among governments, NGOs, manufacturers, and donor agencies aligns resources and objectives, enabling scalable solutions that have a lasting impact on public health.

# Integrated Marketing Approach



**Figure 2: Integrated market approach<sup>9</sup>**

## **CASE STUDIES:**

### **Thailand's Compulsory Licensing:**

In 2006, Thailand issued a compulsory license for the HIV drug efavirenz, allowing local manufacturers to produce generic versions despite existing patents. This move reduced the monthly cost of treatment from approximately US\$41 to US\$20, significantly expanding access to antiretroviral therapy<sup>10</sup>. (NEJM)

### **India's Jan Aushadhi Program:**

The Indian government launched the Jan Aushadhi program to provide generic medicines at highly subsidized prices through dedicated outlets. Awareness campaigns targeted both patients and healthcare providers to build confidence in the quality of generics<sup>11</sup>. (Janaushadhi)

### **Gavi's Advance Market Commitment:**

Gavi introduced an Advance Market Commitment (AMC) for pneumococcal vaccines, pledging US\$1.5 billion from donor countries to guarantee market demand. Vaccines became available in over 60 developing countries at around US\$2 per dose<sup>12</sup>. (Gavi)

### **Clinton Health Access Initiative (CHAI):**

CHAI collaborated with manufacturers to reduce HIV self-testing kit prices to approximately US\$0.80 per test, enabling broad distribution across sub-Saharan Africa<sup>13</sup>. (CHAI)

## **CHALLENGES IN MARKETING AFFORDABLE MEDICINES:**

Obstacles include regulatory and legal barriers, supply chain inefficiencies, financial sustainability, stakeholder coordination, and perceptions of generics. Addressing these barriers is critical to ensure affordability strategies are effective and sustainable<sup>14</sup>. (NCBI)

## **FUTURE DIRECTIONS:**

**Digital Health Technologies:**

Integration of digital technologies, such as e-health platforms, telemedicine, and electronic health records, can improve distribution, track demand, and educate patients and providers<sup>15</sup>. (WHO)

**Public–Private Partnerships:**


Collaborations like Gavi’s AMC demonstrate the potential of PPPs to expand access to affordable medicines by pooling resources, ensuring reliable supply, and negotiating better pricing<sup>12</sup>. (Gavi)

**Education and Awareness:**

Educational campaigns and provider training help build trust in generics and biosimilars, encouraging rational use and increasing uptake<sup>8</sup>. (APHA)

**CONCLUSION**

Effective marketing development of affordable medicines improves access, reduces costs, enhances trust, fosters stakeholder collaboration, and strengthens policy frameworks. Integrated approaches combining pricing, distribution, product strategies, and awareness campaigns can reduce health inequalities and advance global goals for universal health coverage.

**Key outcomes include:**

**Figure 3: Key outcomes of marketing development**

1. Increased access and coverage.
2. Cost reduction through generics and biosimilars
3. Improved trust and utilization
4. Enhanced stakeholder collaboration

5. Strengthened policy and regulatory frameworks<sup>1-20</sup>

## ACKNOWLEDGEMENTS:

We owed the person our deepest gratitude for providing us with the guidance and assistance we needed to complete our assignment. We are quite happy that this task has been completed. We are grateful to Chaya M, a professor in the Pharmaceutical Marketing Management department at Sree Siddaganga College of Pharmacy in Tumkur, for assigning us this task, which aimed to broaden our knowledge and involves some practical work. The administrators and staff of Sree Siddaganga College of Pharmacy in Tumkur, Karnataka, are appreciated by the authors for providing the space needed to conduct this study.

## REFERENCES:

1. World Health Organization. Equitable access to essential medicines: a framework for collective action. Geneva: WHO; 2004.
2. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. *Lancet*. 2017;389(10067):403–76.
3. Pfizer. Accord for a Healthier World [Internet]. Pfizer; 2022 [cited 2025 Oct 1]. Available from: <https://www.pfizer.com>
4. Novartis. Novartis Access Program: Affordable treatment for chronic diseases [Internet]. Novartis; 2015 [cited 2025 Oct 1]. Available from: <https://www.novartis.com>
5. Levine R, Kremer M, Albright A, Wright J. Making markets for vaccines: ideas to action. Washington, DC: Center for Global Development; 2005.
6. Yadav P. Health product supply chains in developing countries: diagnosis of the root causes of underperformance and an agenda for reform. *Health Syst Reform*. 2015;1(2):142–54.
7. UNICEF, Gavi, The Global Fund. Pooled procurement mechanisms in health: case studies and lessons learned. Geneva: UNICEF/Gavi; 2017.
8. Kotwani A. Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all. *BMC Health Serv Res*. 2013;13:285.
9. 't Hoen EFM, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the TRIPS Agreement, 2001–2016. *Bull World Health Organ*. 2018;96(3):185–93.
10. Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. *AIDS*. 2007;21 Suppl 4:S21–9.

11. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generics, using Ireland as a case study. *BMC Pharmacol Toxicol.* 2013;14:1.
12. Medicines Patent Pool. Annual report 2022. Geneva: Medicines Patent Pool; 2022.
13. Mackintosh M, Banda G, Tibandebage P, Wamae W, editors. Making medicines in Africa: the political economy of industrializing for local health. Basingstoke: Palgrave Macmillan; 2016.
14. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *Lancet.* 2009;373(9659):240–9.
15. Moon S, Bermudez J, 't Hoen E. Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? *PLoS Med.* 2012;9(5):e1001218
16. Mackintosh M, Mugwagwa J, Banda G, Wamae W. Health-industry linkages for local health: reframing policies for innovation, access and affordability. *Health Policy Plan.* 2017;32(Suppl 2):ii4–13.
17. Kotwani A. Awareness and perceptions of Jan Aushadhi scheme in India: a study of stakeholders. *J Pharm Policy Pract.* 2019;12:25.
18. Choko AT, Corbett EL, Stallard N, Maheswaran H, Lepine A, Johnson CC, et al. HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care: a pragmatic, randomised controlled trial. *Lancet HIV.* 2015;2(6):e225–31.
19. World Health Organization. Global strategy on digital health 2020–2025. Geneva: WHO; 2021.
20. Gavi, The Vaccine Alliance. Advance Market Commitment for Pneumococcal Vaccines: Annual Report 2015. Geneva: Gavi; 2015.

***AJPTR is***

- Peer-reviewed
- bimonthly
- Rapid publication

Submit your manuscript at: [editor@ajptr.com](mailto:editor@ajptr.com)

